Galena Therapeutics is a clinical-stage biopharmaceutical company developing GLSI-100, a cancer immunotherapy combining a HER2/neu peptide (GP2) with GM-CSF to stimulate immune responses against HER2/neu-expressing cancers. The company's lead program is evaluating GLSI-100 in HER2/neu-positive breast cancer patients, targeting a significant market opportunity given that approximately one-quarter of breast cancers express HER2/neu and half of treated patients experience recurrence despite standard therapy. Galena has licensed exclusive worldwide rights to GP2 technology and relies on contract manufacturers for production while competing against established immunotherapy developers and existing HER2-targeted therapies.